The aim of this study is to define a dose recommendation of vorinostat in pediatric oncology,
to determine pharmacokinetics of vorinostat in children, determine response rates, safety and
feasibility.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Center for Tumor Diseases, Heidelberg
Collaborators:
Merck Sharp & Dohme Corp. University Hospital Heidelberg